BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

CAMBRIDGE, Mass. and BEIJING, China, August 5, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress, taking place on September 18-22, 2020.

Mini Oral Presentations:

Title: Clinical Benefit in Biomarker-Positive Patients (pts) with Locally Advanced or Metastatic Solid Tumors Treated with the PARP1/2 Inhibitor Pamiparib in Combination with Low-Dose (LD) Temozolomide (TMZ)

Mini Oral #: 530MO
Session Title: Developmental Therapeutics
Presenter: Agostina Stradella, M.D. Catalan Institute of Oncology, Spain

Title: BGB-A333, an Anti-PD-L1 Monoclonal Antibody, in Combination with Tislelizumab in Patients with Urothelial Carcinoma

Mini Oral #: 535MO
Session Title: Developmental Therapeutics
Presenter: Juan Martin-Liberal, M.D., Ph.D., Catalan Institute of Oncology, Spain

Poster Presentations:

Title: Phase 2 Study of Pamiparib in Chinese Patients (pts) with Advanced Ovarian Cancer (aOC)

Poster #: 820P
Session Title: Poster Display
Lead Author: Xiaohua Wu, M.D., Ph.D., Fudan University Shanghai Cancer Center, China

Title: Safety and Efficacy of Long-term Exposure (LTE) to Tislelizumab in Chinese Patients with Advanced Solid Tumors

Poster #: 522P
Session Title: Poster Display
Lead Author: Lin Shen, M.D., Ph.D., Peking University Cancer Hospital & Institute, China

Title: Tislelizumab + Chemotherapy vs Chemotherapy Alone as First-line Treatment for Locally Advanced/Metastatic Nonsquamous NSCLC
Poster #: 1263P  
Session Title: Poster Display  
Lead Author: Shun Lu, M.D., Shanghai Chest Hospital, China  

**Title:** Updated Analysis of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC)  

Poster #: 1264P  
Session Title: Poster Display  
Lead Author: Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, China  

**Title:** Investigation of PD-L1 Expression and Tislelizumab Efficacy in Gastroesophageal Adenocarcinoma Using a Novel Tumor and Immune Cell Score with VENTANA PD-L1 (SP263) Assay and Combined Positive Score (CPS)  

Poster #: 154P  
Session Title: Poster Display  
Lead Author: Yee Chao, Ph.D., Taipei Veterans General Hospital, Taiwan  

**About BeiGene**  

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,100+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and Eusa Pharma. To learn more about BeiGene, please visit [www.beigene.com](http://www.beigene.com) and follow us on Twitter at @BeiGeneUSA.

**Investor Contact**  
Craig West  
+1 857-302-5189  
ir@beigene.com  

**Media Contact**  
Liza Heap or Vivian Ni  
+1 857-302-5663 or +1 857-302-7596  
media@beigene.com